Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : transgenics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (9)	9/5/2000 11:50:50 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 41

I'm an EPIcyte shareholder. Thanks for posting this. (eom)

To: nigel bates who wrote (9)	9/5/2000 7:09:20 PM
From: scaram(o)uche	Respond to of 41

make note, Gruntal and Company..... These and other companies can now make monoclonal antibodies rapidly and relatively inexpensively, said Darren Mac, an analyst at Gruntal & Co. "The key question is what sort of yield the companies will get" and whether it's competitive cost-wise, he said of the Dow-EPI partnership. Mac also said there may be similar issues with plant allergens as there were with partially human antibodies. cbs.marketwatch.com